Search results
Showing 1 to 10 of 10 results for fremanezumab
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
This guideline covers the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 764.
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
145,000 people in England to have further treatment choice for preventing migraine attacks
NICE has for the first time recommended an oral treatment for preventing migraines.